Sign up USA
Proactive Investors - Run By Investors For Investors

Marinus Pharmaceuticals Inc shares soar on early study results

Enrollment is continuing in the study with top-line data expected in mid-2017
Marinus Pharmaceuticals Inc shares soar on early study results
The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study, the company said

Shares in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shot up almost 40% as it posted positive clinical study findings.

The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study evaluating its ganaxolone candidate as a treatment for orphan, genetic disorders.

CDKL5 is a severe, rare genetic disorder that results in early-onset, difficult-to-control seizures.

Enrollment is continuing in the study with top-line data expected in mid-2017.

“We are encouraged by the results in these difficult-to-treat pediatric patients,” said Dr. Jaakko Lappalainen, vice president of clinical development at the company.

“Concurrent with completing this study, we will be evaluating the potential for breakthrough therapy and applying for orphan drug designation with the United States Food and Drug Administration.

"CDKL5 pediatric epilepsy may prove to be an attractive and efficient path for ganaxolone and we look forward to evaluating results from the final patients enrolled in this cohort of the study.”

Shares in New York are at US$1.61 - an increase of 38.79% at the time of writing.



Register here to be notified of future MRNS Company articles
View full MRNS profile

Marinus Timeline

Related Articles

AZN2.jpg
September 20 2016
The absence of a discount suggests there is a healthy appetite for the equity.
Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC